CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

PR Newswire Clinical Trials
Original article

/C O R R E C T I O N -- Octapharma/

Data Readoutfibryga®Neutral
AI Analysis

Summary

Octapharma issued a correction to its news release regarding a secondary analysis of the FIBRES trial comparing fibryga to cryoprecipitate for blood component transfusion.

Clinical Trial Data

Importance:1/10
Sentiment:
0.00
correctionfibrygacryoprecipitateFIBRESblood componentstransfusion

Read the original article

Published by PR Newswire Clinical Trials on September 11, 2026 3:36 PM

Read Original